# A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

> **NCT06378593** · PHASE1,PHASE2 · RECRUITING · sponsor: **3H (Suzhou) Pharmaceuticals Co., Ltd.** · enrollment: 130 (estimated)

## Conditions studied

- Solid Tumors With FGFR2 Alterations, Adult

## Interventions

- **DRUG:** 3HP-2827

## Key facts

- **NCT ID:** NCT06378593
- **Lead sponsor:** 3H (Suzhou) Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-17
- **Primary completion:** 2028-06-16
- **Final completion:** 2028-06-16
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06378593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06378593, "A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06378593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*